NASDAQIndustrialsElectrical Equipment & PartsSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ULBI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Support strategic capital expenditures to enhance growth | The company invests in new products and strategic capital spending. | Intact | significant reduction in capital expenditures | Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 7–Nov 5 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is an execution-dependent industrial business, not a proven steady compounder. The long-term thesis is in a watch state: margins improved in the latest quarter, while recent performance remains below its industry cohort and earnings quality is neutral.
ULBI is assessed as cheap versus peers, although the valuation model has low confidence. The expectations gap is positive, but the snapshot labels pricing as unjustified and says valuation is the main source of fragility. Recent risk measures have eased from elevated to moderate.
Near term, earnings execution is a concern: ULBI has missed across recent quarters, and the snapshot flags elevated risk of another miss. In the latest quarter, gross margin rose from 21.3% to 28.9% and operating income moved from a small loss to a profit; management partly credited efficiency work, favorable mix, and a tariff refund. New product investment continues, but product-level revenue delivery is not yet established, and the EnerSys acquisition remains pending.
The multi-year thesis depends on sustaining manufacturing improvements and completing the EnerSys acquisition, which is expected to close in the first quarter of 2027 subject to customary conditions. Near term, another guidance cut would be a meaningful negative, while continued earnings strength from industrial bellwethers ETN, VRT, and BE could support the sector backdrop; weakness at those companies could remove that support.
Over the next 1 to 3 years, the case depends on turning the latest margin progress into repeatable operating results while delivering on the acquisition and product plans. Recent misses and a sector headwind leave meaningful execution risk, despite a valuation assessed as cheap versus peers. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Ultralife Corp's published investment case. The stated target is continue strategic R&D spending. |
| Intact |
| significant cuts to R&D investment |
Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Restore profitability and generate positive net income | Ultralife aims to restore profitability and generate cash flow. | Improving | net income remains negative through FY26 | Net income: $2.368M FY2026-Q3; GAAP. Published target: net income > 0. Annual target cannot be compared with a quarterly or TTM observation. Nov 5, 20262,368,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve revenue growth near $225 million | Analysts expect revenue near $225 million and EPS of $0.93 in 2026. | Under Pressure | revenue falls below $200 million in FY26 | Revenue: $48.271M FY2026-Q3; GAAP. Published target: revenue >= $224.9 million. Annual target cannot be compared with a quarterly or TTM observation. Nov 5, 202648,271,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 17, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.